CRISPR Therapeutics grants Chief Medical Officer Naimish Patel 24,000 stock options, 12,000 restricted stock units

CRSP•2026-10-28

CRISPR Therapeutics granted Chief Medical Officer Naimish Patel 24,000 stock options and 12,000 restricted stock units on October 26, 2026. The options expire on October 26, 2036.

1. Equity awards

CRISPR Therapeutics granted Chief Medical Officer Naimish Patel 24,000 stock options and 12,000 restricted stock units on October 26, 2026. The stock options expire on October 26, 2036.

Sources

CRISPR Therapeutics grants Chief Medical Officer Naimish Patel 24,000 stock options, 12,000 restricted stock units

Sec

CRISPR Therapeutics grants Chief Medical Officer Naimish Patel 24,000 stock options, 12,000 restricted stock units

1. Equity awards

Related News

Nova Minerals publishes revised annual report

B&G Foods declares quarterly dividend of $0.095 per share

Zone Frontier publishes amended annual report

Sources

CRISPR Therapeutics grants Chief Medical Officer Naimish Patel 24,000 stock options, 12,000 restricted stock units

Kinross reports 2026 third-quarter results

SailPoint director James Malcolm Hagan reports sale of $94,612.50 in common shares